Sun Pharma Q4 Results 2025: Q4 PAT Down By 19% To ₹2,154 crores; Final Dividend of ₹5.50 per Share Declared
Updated: 23 May 2025 • 7:40 pm
Posted by:
Sun Pharma Q4 Results 2025: The pharma company reported a downgrade in its PAT in the Q4 results declared on 22nd May 2025. Sun Pharma Limited clocked a total revenue from operations of ₹12,958.8 crores, up 8.14% YoY. The company's PAT for the period under review dipped significantly by 19% to ₹2,1539.93 crore, compared with the PAT of Q4 FY24. However, even after a decreased profit, Sun Pharma has declared a final dividend of ₹5.50 per share for FY25.
Sun Pharma Q4 Results 2025: Extracts of Q4 FY25 and FY25 Financials
| Particular | Quarter Ended | Year Ended | ||
| 31 – 03 – 2025 | 31 – 03 – 2024 | 31 – 03 – 2025 | 31-03-2024 | |
| Revenue From Operations | ₹12,958.84 | ₹11,982.90 | ₹52,578.44 | ₹48,496.85 |
| Profit Before Tax (PBT) | ₹3,254.35 | ₹2,815.52 | ₹13,752.13 | ₹11,087.89 |
| Net Profit | ₹2,153.93 | ₹2,658.74 | ₹10,964.75 | ₹9,610.03 |
| EPS (Basic & Diluted) | 9.0 | 11.1 | 45.6 | 39.9 |
*Figures in crores except EPS
Sun Pharma Q4 Results 2025 Highlights: Consolidated Figures
- Sun Pharma Limited clocked a total revenue from operations of ₹12,958.84 crores, 8% YoY up in Q4 FY25. During the full fiscal year 2025, the company's revenue stood at ₹52,578.44 crores.
- On the profit front, the company took a hit of 19% quarterly. However, Sun Pharma registered a growth of more than 10% in its full-year PAT figures.
- The company's EPS (basic and diluted) for Q4 FY25 stood at 9.0 against 11.1 in Q4 FY24.
- The PBT of Sun Pharma Limited increased by 15.58% in Q4 FY25 to ₹3,254.35 crores.
Sun Pharma Limited Share Price Performance
Sun Pharma shares opened with a loss of 3.53% at a level of ₹1,658.00 on 23rd May 2025. This opening dip can be associated with a negative investor sentiment due to weak Q4 profits. During the intraday trading, the company's share price touched a day high of ₹1,689.50, still lower than the previous closing of ₹1,718.70. On the closing bell on 23rd May 2025, Sun Pharma shares closed at a level of ₹1,689.10, 1.72% lower.
For regular stock updates, dividend alerts, and expert verdicts, stay informed with Univest!
Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.
Recent News Articles
Unified Data Tech IPO GMP: Day 1 IPO Live Updates
Stock Market Today: Sensex Plunged 800 Points & Nifty50 By 0.9%; Check Key Insights
Best Semiconductor Stocks in India 2025
Unified Data- Tech IPO Review: Know GMP and other IPO Details; Should You Apply or Not?
United Spirits Q4 Results 2025: Net Profit Grows to ₹421 Crores and EBITDA Climbs by 37.7%.
Stock Market Today: Sensex Soar 119 Points & Nifty50 By 0.09%; Check Key Insights
Hindalco Q4 Results 2025 Declared 66% Rise in Profit and 16% Surge in Revenue: Check Key Highlights
Stocks to Watch Today: 21st May 2025 | Dixon, GSFC, United Spirits, IRCON, Zaggle, & More!
Recent Articles
Gold Price Today, 30 October 2026: MCX Gold Falls 1.25% to Rs 1,40,808 Per 10 Grams and Spot Gold Slips Below $4,000, a 3.5-Month Low, as December Fed Hike Bets Build Ahead of Dhanteras
30 October 2026
Anthropic IPO Valuation: Aswath Damodaran Values the Claude Maker at $1.475 Trillion, Just Below the Reported $1.5 to $2 Trillion IPO Range, With Scenarios From Negative $373 Billion to $4.04 Trillion
30 October 2026
Equitas Small Finance Bank Share Price Crashes 10% to Rs 51.25 on 30 October 2026, Down 21% in Two Days After CEO PN Vasudevan Resigns Despite Record Equitas Q2 Results: What Is Going On?
30 October 2026
Greaves Cotton Share Price Jumps 10% Despite 81% Fall in Q2 Profit: What Is Driving the Rally?
30 October 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Gold Price Today, 30 October 2026: MCX Gold Falls 1.25% to Rs 1,40,808 Per 10 Grams and Spot Gold Slips Below $4,000, a 3.5-Month Low, as December Fed Hike Bets Build Ahead of Dhanteras
Anthropic IPO Valuation: Aswath Damodaran Values the Claude Maker at $1.475 Trillion, Just Below the Reported $1.5 to $2 Trillion IPO Range, With Scenarios From Negative $373 Billion to $4.04 Trillion
Equitas Small Finance Bank Share Price Crashes 10% to Rs 51.25 on 30 October 2026, Down 21% in Two Days After CEO PN Vasudevan Resigns Despite Record Equitas Q2 Results: What Is Going On?
Greaves Cotton Share Price Jumps 10% Despite 81% Fall in Q2 Profit: What Is Driving the Rally?
Asian Paints Share Price After Q2 Results: Profit Up 7%, but Price Hikes Are Yet to Brighten Margins
Popular this week
Borosil Share Price Jumps 16% After Strong Q2 Results: Record Profit, Margin Jump and Key Price Levels to Know
Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times